There is a Tibetan saying: Tragedy should be utilised as a source of strength.
When our charity was started in 2013, it was as a result of unspeakable tragedy and sadness – the death of Alexander Jansons at age 18. The Jansons family however, refused to give in, and vowed that they would take this rare, never talked about, totally misunderstood and relatively ignored heart condition and make it heard of, make it be talked about and most importantly, make it be researched to save lives.
Over the years, the research into myocarditis in the UK grew from humble beginnings to become a presence to be acknowledged and reckoned with. A number of important findings have been published over the years but the latest paper, Genetic Architecture of Acute Myocarditis and the Overlap with Inherited Cardiomyopathy, takes 8 years of cumulative research on genetics and turns it into something extraordinary. For the first time we can know exactly which hearts are predisposed and which are susceptible to myocarditis along with who should be safe.
This latest research opens the pathways for clearer understanding in the treatment of myocarditis with targeted treatment rather than generic approaches. We can now begin to look at how to “turn off” these genes and take the first significant steps to a cure.
We are proud to say that a paper of this magnitude and significance is only released every 3-5 years and to have our research highlighted by the American Heart Association as being an important step in understanding myocarditis with the expectation is that it will change the guidelines on how myocarditis patients are evaluated and eventually treated is, well, truly incredible.
This is what the American Heart Association had to say on our research:
“Gene abnormalities may make some people more susceptible to myocarditis, a rare type of heart inflammation that can affect young people and athletes, a large new study shows.
The findings, published Monday in the American Heart Association journal Circulation, could partially answer why otherwise healthy young people sometimes develop a condition that can lead to heart failure and sudden cardiac death, researchers said.
In the rare instances when it happens, myocarditis “often affects young patients in the prime of life, and we’ve never understood why,” said senior study author Dr. Sanjay Prasad, a professor of cardiomyopathy at the Imperial College London in the United Kingdom. He also is a consultant cardiologist at Royal Brompton Hospital in London.
The new, population-based study suggests that “it’s not just random,” he said. “For a subset of people, there’s a gene that predisposes them to this, or makes them susceptible.”
Myocarditis, an inflammation of the heart, frequently is triggered by a virus. The condition can progress to heart muscle disease that weakens the heart and its ability to pump blood. Myocarditis usually resolves on its own or with treatment, but in some cases it can cause lasting damage. It also can be fatal.
Previously undetected and untreated myocarditis has been identified as the cause of sudden death in 8% of 1- to 17-year-olds and 9% of athletes. Postmortem studies suggest it may be responsible for 3% to 12% of all sudden cardiac deaths.
Studies have found a small but increased risk of myocarditis following COVID-19 infection and an even smaller, but still elevated, risk after COVID-19 vaccination.
The new research involved two types of heart muscle disease associated with myocarditis. Dilated cardiomyopathy, the most common type, typically affects adults under age 50. It occurs when the heart muscle dilates, becoming thin and enlarging the heart’s chambers, making blood pumping more difficult. In arrhythmogenic cardiomyopathy, heart muscle is replaced by scarring and fat, causing changes in heart rhythms.
Researchers analyzed DNA sequencing data for 336 people with acute myocarditis and 1,053 healthy people in the U.K. and the Netherlands, looking for genetic variants associated with the two types of cardiomyopathy. Both groups were predominantly men.
The participants were followed for five years. Among those who had myocarditis, 8% – or 1 in 13 – had genetic variants associated with the cardiomyopathies, compared with fewer than 1% of those without myocarditis.
While this data was collected between 2016 and 2018, prior to the COVID-19 pandemic, Prasad said others are now studying whether a subset of people with COVID-19-related myocarditis or COVID-19 vaccine-related myocarditis also had these genetic variants.
If supported by other studies, the findings could impact care for people with myocarditis and their families, the authors said.
“These findings suggest there should be a low threshold for genetic testing in patients who present with myocarditis – particularly when there isn’t an obvious reason for it,” said Dr. Amrit Lota, the study’s lead author and a consultant cardiologist at Royal Brompton Hospital.
People with a family history of myocarditis or cardiomyopathy – along with young patients with poor heart function, frequent heart rhythm disturbances or who have a lot of scarring on heart MRIs – also should be considered for testing, he said.
Dr. Adam Helms, a cardiologist and assistant professor at the University of Michigan Frankel Cardiovascular Center in Ann Arbor, said he routinely conducts genetic testing on patients with myocarditis for his research and was not surprised to see genetic variants associated with the condition. Helms was not involved in the new study.
“What this study did was they found it to be true in a very large cohort,” he said. “This presents a strong case for genetic testing.”
Knowing someone has a genetic variant associated with myocarditis could affect the type of treatment provided, he said.
“Sometimes cases of myocarditis are treated with immunosuppression,” Helms said. “But this is not the best way to treat hereditary cases. There are no studies to suggest those cases would improve.”
Medications such as beta blockers might be more effective for people genetically predisposed to myocarditis, Helms said, because they may have a higher risk of future heart problems, such as heart failure.
Prasad said his team was continuing to follow the people in this study – as well as expanding it to include more patients – to find out how those with the genetic variants fared over the long term. Future investigations also would analyze data across ethnicities and gender to look for differences among specific groups.”
Our motto has always been Finding Tomorrows Cures Today and today, well, today we are firmly on that road. Say what you want but I think we will always embody the #SmallButMighty.
